Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin | Zendy

Jan Bolinder | Zendy; Östen Ljunggren | Zendy; Joel Kullberg | Zendy; Lars Johansson | Zendy; John Wilding | Zendy; Anna Maria Langkilde | Zendy; Jennifer Sugg | Zendy; Shamik Parikh | Zendy

Open Access

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Author(s) -

Jan Bolinder,

Östen Ljunggren,

Joel Kullberg,

Lars Johansson,

John Wilding,

Anna Maria Langkilde,

Jennifer Sugg,

Shamik Parikh

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2260

Subject(s) - dapagliflozin , medicine , metformin , body mass index , endocrinology , adipose tissue , placebo , type 2 diabetes , weight loss , glycemic , waist , urology , diabetes mellitus , obesity , alternative medicine , pathology

Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research